The short version of gamma-glutamyl cycle fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-24 and is reviewed periodically as new material appears.
Cells synthesize glutathione through two ATP-dependent enzymatic steps. The first step combines glutamate and cysteine to form gamma-glutamylcysteine, catalyzed by glutamate-cysteine ligase. The second step adds glycine, producing the complete tripeptide, catalyzed by glutathione synthetase. Glutathione itself can inhibit the first enzyme, providing negative feedback when levels are high. Because cysteine is often limiting, its availability influences how quickly the pathway proceeds. These reactions occur in the cytosol, and the resulting glutathione can be distributed to other compartments.
Glutathione functions in redox balance, detoxification, and sulfur amino acid storage. It participates in reactions that help maintain ascorbate and protein thiol status. The molecule serves as a cofactor for several enzymes, including glutathione peroxidases and glutathione S-transferases. These enzymes reduce peroxides and conjugate electrophiles, respectively. Glutathione also contributes to the metabolism of xenobiotics and to the transport of cysteine between tissues. How interorgan transport and tissue-specific regulation shape whole-body pools remains an active area of study.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. Its cysteine residue carries a thiol group, which allows the molecule to participate in reduction and oxidation reactions. The compound exists in most living cells, where the reduced form, often abbreviated GSH, is usually more abundant than the oxidized disulfide form, GSSG. Intracellular concentrations are commonly in the millimolar range, while extracellular concentrations are much lower. This uneven distribution supports its role as a major cellular redox buffer.
Glutathione participates in detoxification reactions, amino acid transport, and the maintenance of protein thiols. It serves as a cofactor for several enzymes, including glutathione peroxidases and glutathione S-transferases. In research literature, altered glutathione status appears in studies of aging, infection, metabolic stress, and environmental exposure. Whether low glutathione is a cause, consequence, or marker of such conditions often remains unresolved. Direct measurement in blood or tissue provides a snapshot, but results depend on sample handling, timing, and the method used.
Glutathione is a small tripeptide made of glutamic acid, cysteine, and glycine. Its cysteine thiol group allows reversible oxidation and reduction, making it central to cellular redox chemistry. The reduced form, often abbreviated GSH, predominates inside most cells, while the oxidized disulfide form, GSSG, forms when two GSH molecules react. The ratio of GSH to GSSG is widely used as an indicator of oxidative stress in laboratory research, though it does not by itself diagnose a clinical condition.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C10H17N3O6S | Reduced glutathione (GSH) |
| Molar mass | 307.32 g/mol | Calculated for C10H17N3O6S |
| Appearance | White to off-white powder | Typical solid form |
| Solubility | Water-soluble | Polar tripeptide |
| Common synonyms | GSH; L-glutathione | Gamma-glutamylcysteinylglycine |
Glutathione synthesis proceeds in two ATP-dependent steps catalyzed by glutamate-cysteine ligase and glutathione synthetase. The first step joins glutamate and cysteine to form gamma-glutamylcysteine and is generally rate-limiting. The second step adds glycine to complete the tripeptide. Cysteine availability, feedback inhibition by glutathione, and oxidative conditions influence flux through this pathway. The pathway is conserved across many organisms, and degradation by gamma-glutamyl transpeptidase and related peptidases recycles amino acids for new synthesis.
Within cells, glutathione serves as a cofactor for glutathione peroxidases and glutathione S-transferases. These enzymes reduce hydrogen peroxide and organic peroxides or conjugate electrophilic compounds to the thiol group. The resulting conjugates can be exported and processed through mercapturic acid pathways. Glutathione also contributes to protein thiol homeostasis and to recycling of other antioxidants such as ascorbate. Its precise roles vary by tissue, and many regulatory effects observed in laboratory systems remain difficult to quantify in whole organisms.
Glutathione is a small tripeptide built from glutamate, cysteine, and glycine. The peptide bond between glutamate and cysteine uses the gamma-carboxyl group, a linkage that resists ordinary peptidases. Cells make it in two ATP-dependent steps: gamma-glutamylcysteine synthetase joins glutamate and cysteine, then glutathione synthetase adds glycine. The pathway is feedback-inhibited by glutathione itself, so intracellular levels tend to stay within a narrow range. Because cysteine is often limiting, sulfur amino acid supply influences how much glutathione a cell can produce.
In its reduced form, glutathione carries a sulfhydryl group that can donate electrons. This property lets it act as a major cellular antioxidant and redox buffer. Glutathione peroxidase uses it to reduce hydrogen peroxide and lipid peroxides, while glutathione reductase regenerates the reduced form using NADPH. The ratio of reduced glutathione to glutathione disulfide is widely used as an indicator of oxidative stress, though the ratio changes with compartment, cell type, and sample handling. Oxidized glutathione can also form mixed disulfides with proteins, affecting their activity.
Cells synthesize glutathione through two ATP-dependent steps: glutamate-cysteine ligase joins glutamate and cysteine, and glutathione synthetase adds glycine to form the complete tripeptide. Breakdown occurs through gamma-glutamyl transpeptidase and subsequent peptidase reactions, forming the gamma-glutamyl cycle. Within cells, glutathione also forms a disulfide-linked dimer called GSSG when two GSH molecules react. The balance between GSH and GSSG is widely used as an indicator of oxidative conditions, although the ratio can vary by compartment and tissue.
Glutathione supports several cellular processes beyond direct antioxidant action. It serves as a cofactor for glutathione peroxidase and glutathione S-transferase enzymes, which reduce peroxides and conjugate electrophiles, respectively. The molecule also acts as a reservoir of cysteine, an amino acid that can limit protein synthesis and redox signaling. In human nutrition, oral glutathione is sold as a supplement, but how much intact glutathione reaches tissues after ingestion remains an active research question. Clinical claims about supplementation are not uniformly supported by controlled trials.
Glutathione is a small tripeptide built from glutamic acid, cysteine, and glycine. Its peptide bond between glutamate and cysteine involves the gamma-carboxyl group rather than the usual alpha-carboxyl group. This structure gives the molecule a reactive thiol on the cysteine residue. The reduced form, often abbreviated GSH, is the predominant intracellular species in many cell types. Because the thiol can donate electrons, glutathione participates in redox chemistry and in the conjugation of reactive molecules.
== Causes == Pulmonary infection by bacteria, viruses and parasites Drugs: antineoplastic drugs, erlotinib, amiodarone Chemical exposure, most notably to diacetyl Vaping: On October 17, 2019, the American Journal of Clinical Pathology reported that lung biopsies from patients with vaping-associated pulmonary illness show acute lung injury patterns, including organizing pneumonia. Ionizing radiations Inflammatory diseases Systemic lupus Rheumatoid arthritis (RA-associated COP) Scleroderma Bronchial obstruction Proximal bronchial squamous cell carcinoma SARS-CoV-2 Analysis of COVID-19 CT imaging along with postmortem lung biopsies and autopsies suggest that the majority of patients with COVID-19 pulmonary involvement also have secondary organizing pneumonia (OP) or its histological variant, acute fibrinous and organizing pneumonia, which are both well-known complications of viral infections. It was identified in 1985, although its symptoms had been noted before but not recognised as a separate lung disease. The risk of COP is higher for people with inflammatory diseases like lupus, dermatomyositis, rheumatoid arthritis, and scleroderma. It most commonly presents in the 5th or 6th decade of life and it is exceedingly rare in children.
The IQOS is a heated tobacco product marketed by Philip Morris International. It heats tobacco at a lower temperature than traditional cigarettes. The tobacco sticks reach a temperature up to 350 °C. It sold first in Japan since November 2014. In December 2016, the United Tobacco Vapor Group's (UTVG) stated that they have been given a patent for their vaporizing component system. QMOS from UTVG does not contain a wick or sponge and the number of components is 5 compared to 20 for traditional e-cigarettes. Pax Labs has developed vaporizers that heats the leaves of tobacco to deliver nicotine in a vapor. In June 2015, they introduced Juul, a type of e-cigarette which delivers 10 times as much nicotine as other e-cigarettes, equivalent to an actual cigarette puff. Juul was spun off from Pax Labs in June 2017 and is now available by the independent company Juul Labs. The eTron 3T from Vapor Tobacco Manufacturing, launched in December 2014, employs a patented, aqueous system whereby the tobacco is extracted into water. The e-liquid contains organic tobacco, organic glycerin, and water. In December 2013, Japan Tobacco launched Ploom in Japan. In January 2016, they launched Ploom TECH that produces a vapor from a heated liquid that moves through a capsule of granulated tobacco leaves. In 2016, British American Tobacco (BAT) released its own version of the heat but not burn technology called glo in Japan and Switzerland. It uses tobacco sticks rather than nicotine liquid, and does not directly heat or burn tobacco.
=== Nanoparticle-based Controlled-Release === The use of nanotechnology into drug delivery has opened the door to new possibilities, particularly with the development of nanoparticle-based controlled-release systems. These systems are designed to deliver drugs more precisely and over longer periods of time helping with targeted sites and therapeutic effects. Tiny carriers, such as liposomes, dendrimers, and polymeric nanoparticles, can hold medication and release them at controlled rates. Some are even engineered to respond to specific conditions in the body. For instance, acidic microenvironment commonly found in tumor tissues can be used to trigger drug release at the site needed. This targeted approach helps minimize side effects by limiting exposure to the rest the body. Thus, making treatment more effective. Recent studies have shown the effectiveness of smart nanoparticles that respond to biological cues, such as pH or redox conditions, thereby delivering drugs more precisely to tumor sites. For instance, pH-sensitive nanoparticles take advantage of the lower pH in tumor cells to release the drugs, which boost effectiveness while protecting healthy cells. Additionally, the use of biocompatible materials and switching the nanoparticle surfaces have improved their accuracy and release of delivery systems. Advances in design have also made it possible to create multi-functional nanoparticles that are capable of handling tough challenges like multi-drug resistance in cancer.
Penalties for violations of Stark Law include: denial of payment for the DHS provided; refund of monies received by physicians and facilities for amounts collected; payment of civil penalties of up to $15,000 for each service that a person "knows or should know" was provided in violation of the law, and three times the amount of improper payment the entity received from the Medicare program; exclusion from the Medicare program and/or state healthcare programs including Medicaid; and payment of civil penalties for attempting to circumvent the law of up to $100,000 for each circumvention scheme.
== Materials science == Materials science has applied the techniques of combinatorial chemistry to the discovery of new materials. This work was pioneered by P.G. Schultz et al. in the mid-nineties in the context of luminescent materials obtained by co-deposition of elements on a silicon substrate. His work was preceded by J. J. Hanak in 1970 but the computer and robotics tools were not available for the method to spread at the time. Work has been continued by several academic groups as well as companies with large research and development programs (Symyx Technologies, GE, Dow Chemical etc.). The technique has been used extensively for catalysis, coatings, electronics, and many other fields. The application of appropriate informatics tools is critical to handle, administer, and store the vast volumes of data produced. New types of design of experiments methods have also been developed to efficiently address the large experimental spaces that can be tackled using combinatorial methods.
Sources: en.wikipedia.org
Zimelidine was introduced in 1982 and was the first SSRI to be sold. Despite its efficacy, a statistically significant increase in cases of Guillain–Barré syndrome among treated patients led to its withdrawal in 1983. Fluoxetine, introduced in 1987, is commonly thought to be the first SSRI to be marketed.
== History == Efficacy was evaluated in TROPION-Breast01 (NCT05104866), a multicenter, open-label, randomized trial. Participants must have experienced disease progression, been deemed unsuitable for further endocrine therapy, and have received one or two lines of prior chemotherapy for unresectable or metastatic disease. Participants were excluded for a history of ILD/pneumonitis requiring steroids, ongoing ILD/pneumonitis, clinically active brain metastases, or clinically significant corneal disease. Participants also were excluded for ECOG performance status >1. Randomization was stratified by previous lines of chemotherapy, prior CDK4/6 inhibitor treatment, and geographical region. A total of 732 participants were randomized (1:1) to datopotamab deruxtecan (n=365) or investigator's choice of chemotherapy (n=367); eribulin (60%), capecitabine (21%), vinorelbine (10%), or gemcitabine (9%). Efficacy was evaluated in a pooled subgroup of 114 participants with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer who had received prior treatment with an epidermal growth factor receptor-directed therapy and platinum-based chemotherapy and received datopotamab deruxtecan at the recommended dose across two clinical trials: TROPION-Lung05 and TROPION-Lung01. TROPION-Lung05 (NCT04484142) was a multi-center, single-arm trial, while TROPION-Lung01 (NCT04656652) was a multi-center, open-label, randomized controlled trial.
In practice, Sucre depended so much on the orders of Bolívar that he was quickly seen by Peruvians and people of the River Plate as a puppet or bridgehead of the Liberator in the continental south, a “proconsul of the Bolivian empire”. "You can't think of the multitude of papers that come from Peru to upset Bolivia. Until today they have had no influence, but perhaps in the long run they will do something. the Argentines. I am happy about this because I will be able to carry out the project of the federation of Chile, Bolivia and Buenos Aires." Subsequently, Sucre would have carried out an intense campaign to seize Arica from Peru and give it to Bolivia for its annexation to a natural outlet to the sea, proposing it in October 1826, he also warned Bolívar, during one of his letters of the year 1828, about the danger that Peru would be for Gran Colombia: "If Peru conquers Bolivia and keeps it, the South of Colombia (current Ecuador) runs a thousand and a thousand risks." To this is added the testimony of the Argentine minister M. Bustos, who on October 27, 1828, said in the Buenos Aires newspaper "El Tiempo" that Sucre and Gamarra had put together a plan to make Bolívar the Emperor of South America, separating Puno, Arequipa and Cuzco from the Republic of Peru, something Bolívar was aware of but did not want to make a false step. The centralism of the capital only produced new supporters of federalism and, in some cases, of secession, in Arequipa.
==== Wound cleansing solutions ==== There is insufficient evidence to determine if cleaning wounds is beneficial or whether wound cleaning solutions (polyhexamethylene biguanide, aqueous oxygen peroxide, etc.) are better than sterile water or saline solutions to help venous leg ulcers heal. It is uncertain whether the choice of cleaning solution or method of application makes any difference to venous leg ulcer healing.
Sources: en.wikipedia.org
Glutathione is built from three amino acids: glutamate, cysteine, and glycine. The linkage involves the gamma-carboxyl group of glutamate rather than the alpha-carboxyl group, which is unusual for peptides. This structure protects the bond from some common peptidases.
It is present in nearly all cells, with notable amounts in the liver, kidneys, and red blood cells. The highest intracellular concentrations are usually in the millimolar range. Levels differ by tissue, age, and physiological state.
It is not classified as an essential nutrient because cells can synthesize it from amino acids. Dietary sources exist, but their contribution to tissue pools is not fully established. The body's production depends on enzyme activity and precursor availability.
GSH is the reduced form of glutathione, with a free thiol group on cysteine. GSSG is the oxidized disulfide form, created when two GSH molecules become linked. The two forms exist together, and their balance is often reported as the GSH/GSSG ratio in laboratory studies.